10 Hottest Mega-Cap Stocks So Far in 2025

9. Thermo Fisher Scientific Inc (TMO)

• YTD Total Return: 6.21%

If you’ve ever benefited from a diagnostic test at a hospital, or taken medicine for a serious condition, there’s a good chance Thermo Fisher (NYSE:TMO) had a hand in making it possible.

Thermo Fisher (NYSE:TMO)’s recent quarters have revealed steady (though not always spectacular) top-line results. In their third quarter of 2024, they reported around $10.6 billion in revenue — virtually flat over the previous year — and an adjusted EPS of $5.28. The company still projects its annual revenue to land between $42.4 billion and $43.3 billion, with adjusted EPS in the neighborhood of $21.35 to $22.07 for 2024.

On the stock market side, Thermo Fisher (NYSE:TMO) had hovered in the low-to-mid-$500s in early January 2025. In my view, that reticence is pretty standard for a large-cap science services provider when overall biotech and pharmaceutical markets are a bit unpredictable. But the fact that the company is still holding quarterly earnings calls with stable guidance and regularly issuing dividends signals that top management feels comfortable with Thermo Fisher’s cash flow.

Regardless, TMO makes the list due to a recent recovery from a selloff that started after its Q3 report. The stock has mostly traded sideways since 2021 and I see no reason to believe that it will deliver spectacular returns this year.